Skip to content
2000
image of Nutraceuticals in Depression Management: Current Evidence and Perspectives

Abstract

Background

Depression is a common psychiatric disorder characterized by feelings of sadness, diminished interest in activities, and disruptions in sleep patterns. Pharmaco-therapy, which often involves the use of antidepressant medicines, are method for managing depression. There are potential negative effects linked to the utilization of these medicines, even though many people have found them to be beneficial.

Objective

Traditional pharmacological therapies for depression can have a variety of adverse effects or drawbacks. To overcome these constraints, nutraceuticals have come into the picture of interest. Nutraceuticals, which are naturally derived compounds with potential therapeutic benefits, have attracted interest as an innovative approach to treating depression. In this review, the efficacy of nutraceuticals in depression will be discussed.

Methods

To find pertinent research on nutraceuticals in the treatment of depression, a thorough literature analysis was enacted. Studies investigating the significance of nutraceuticals on depression signs, patent perspectives, and clinical studies were included.

Results

The findings suggest that several nutraceuticals, including omega-3 fatty acids, dietary fibers, and phytochemicals, including Ashwagandha and valerian, exhibit antidepressant effects. These compounds have shown promising results in improving depressive symptoms, enhancing neuroplasticity and neurogenesis, and regulating neurotransmitter imbalances.

Conclusion

Nutraceuticals offer a novel approach to depression, providing potential benefits in alleviating depressive symptoms. Correlative review suggests that increasing intake of these substances could be an alternate method for delaying the early symptoms and course of depression. Supplementation with dietary fibers, Omega-3 fatty acids, and phytochemicals can be utilized as a complementary strategy for anti-depressant therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rafna/10.2174/012772574X361750250323111150
2025-05-07
2025-09-26

  • From This Site

    /content/journals/rafna/10.2174/012772574X361750250323111150
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hu S. Chen G. Tu H. Epidemiology of depression in patients with psoriasis: A nationwide population-based cross-sectional study. Acta Derm. Venereol. 2019 99 6 530 538 10.2340/00015555‑3145 30734048
    [Google Scholar]
  2. Alvarez-Mon M.A. Ortega M.A. García-Montero C. Fraile-Martinez O. Monserrat J. Lahera G. Mora F. Rodriguez-Quiroga A. Fernandez-Rojo S. Quintero J. Alvarez-Mon M. Exploring the role of nutraceuticals in major depressive disorder (MDD): Rationale, state of the art and future prospects. Pharmaceuticals (Basel) 2021 14 8 821 10.3390/ph14080821 34451918
    [Google Scholar]
  3. Ormel J. Cuijpers P. Jorm A. Schoevers R.A. What is needed to eradicate the depression epidemic, and why. Ment. Health Prev. 2020 17 200177 10.1016/j.mhp.2019.200177
    [Google Scholar]
  4. Medeiros G.C. Roy D. Kontos N. Beach S.R. Post-stroke depression: A 2020 updated review. Gen. Hosp. Psychiat. 2020 66 70 80 10.1016/j.genhosppsych.2020.06.011 32717644
    [Google Scholar]
  5. Grover S. Dutt A. Avasthi A. An overview of Indian research in depression. Indian J. Psychiat. 2010 52 7 Suppl. 1 178 10.4103/0019‑5545.69231 21836676
    [Google Scholar]
  6. Sullivan P.F. Neale M.C. Kendler K.S. Genetic epidemiology of major depression: Review and meta-analysis. Am. J. Psychiat. 2000 157 10 1552 1562 10.1176/appi.ajp.157.10.1552 11007705
    [Google Scholar]
  7. Øverland S. Woicik W. Sikora L. Whittaker K. Heli H. Skjelkvåle F.S. Sivertsen B. Colman I. Seasonality and symptoms of depression: A systematic review of the literature. Epidemiol. Psychiatr. Sci. 2020 29 e31 10.1017/S2045796019000209 31006406
    [Google Scholar]
  8. World Health Organization. Depressive Disorder (Depression). 2023 Available from: https://www.who.int/news-room/fact-sheets/detail/depression
  9. Sagar R. Selvakumar N. Prevalence of depression in Indian adolescents. Indian J. Pediatr. 2021 88 5 427 428 10.1007/s12098‑021‑03750‑4 33825129
    [Google Scholar]
  10. Katon W. Unützer J. Russo J. Major depression: The importance of clinical characteristics and treatment response to prognosis. Depress. Anxiety 2010 27 1 19 26 10.1002/da.20613 19798766
    [Google Scholar]
  11. Jablensky A. Johnson R. Bunney W. Cruz M. Durkin M. Familusi J. Gourie-Devi M. Jamison D. Jenkins R. Neurological, psychiatric, and developmental disorders; meeting the challenge in the developing world. Washington (DC) National Academy Press, US 2001 10.17226/10111 25057559
    [Google Scholar]
  12. Kalin N.H. The critical relationship between anxiety and depression. Am. J. Psychiat. 2020 177 5 365 367 10.1176/appi.ajp.2020.20030305 32354270
    [Google Scholar]
  13. Mao Y. Zhang N. Liu J. Zhu B. He R. Wang X. A systematic review of depression and anxiety in medical students in China. BMC Med. Educ. 2019 19 1 327 10.1186/s12909‑019‑1744‑2 31477124
    [Google Scholar]
  14. Jacobson N.C. Newman M.G. Perceptions of close and group relationships mediate the relationship between anxiety and depression over a decade later. Depress. Anxiety 2016 33 1 66 74 10.1002/da.22402 26290461
    [Google Scholar]
  15. Tiller J.W.G. Depression and anxiety. Med. J. Aust. 2013 199 S6 S28 S31 10.5694/mja12.10628 25370281
    [Google Scholar]
  16. Andersson D. Magnusson H. Carstensen J. Borgquist L. Co-morbidity and health care utilisation five years prior to diagnosis for depression. A register-based study in a Swedish population. BMC Public Health 2011 11 1 552 10.1186/1471‑2458‑11‑552 21749713
    [Google Scholar]
  17. Abela J.R.Z. Skitch S.A. Dysfunctional attitudes, self-esteem, and hassles: Cognitive vulnerability to depression in children of affectively ill parents. Behav. Res. Ther. 2007 45 6 1127 1140 10.1016/j.brat.2006.09.011 17074303
    [Google Scholar]
  18. Bifulco A. Moran P.M. Baines R. Bunn A. Stanford K. Exploring psychological abuse in childhood: II. Association with other abuse and adult clinical depression. Bull. Menninger Clin. 2002 66 3 241 258 10.1521/bumc.66.3.241.23366 12448629
    [Google Scholar]
  19. Infurna M.R. Reichl C. Parzer P. Schimmenti A. Bifulco A. Kaess M. Associations between depression and specific childhood experiences of abuse and neglect: A meta-analysis. J. Affect. Disord. 2016 190 47 55 10.1016/j.jad.2015.09.006 26480211
    [Google Scholar]
  20. Katon W.J. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol. Psychiat. 2003 54 3 216 226 10.1016/S0006‑3223(03)00273‑7 12893098
    [Google Scholar]
  21. Lopizzo N. Bocchio Chiavetto L. Cattane N. Plazzotta G. Tarazi F.I. Pariante C.M. Riva M.A. Cattaneo A. Gene-environment interaction in major depression: Focus on experience-dependent biological systems. Front. Psychiat. 2015 6 68 10.3389/fpsyt.2015.00068 26005424
    [Google Scholar]
  22. Luppa M. Sikorski C. Luck T. Ehreke L. Konnopka A. Wiese B. Weyerer S. König H.H. Riedel-Heller S.G. Age- and gender-specific prevalence of depression in latest-life – Systematic review and meta-analysis. J. Affect. Disord. 2012 136 3 212 221 10.1016/j.jad.2010.11.033 21194754
    [Google Scholar]
  23. Stikkelbroek Y. Bodden D.H.M. Kleinjan M. Reijnders M. van Baar A.L. Adolescent depression and negative life events, the mediating role of cognitive emotion regulation. PLoS One 2016 11 8 e0161062 10.1371/journal.pone.0161062 27571274
    [Google Scholar]
  24. Nielson D.M. Keren H. O’Callaghan G. Jackson S.M. Douka I. Vidal-Ribas P. Pornpattananangkul N. Camp C.C. Gorham L.S. Wei C. Kirwan S. Zheng C.Y. Stringaris A. Great expectations: A critical review of and suggestions for the study of reward processing as a cause and predictor of depression. Biol. Psychiat. 2021 89 2 134 143 10.1016/j.biopsych.2020.06.012 32797941
    [Google Scholar]
  25. Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin. Neurosci. 2022 4 1 7 20 10.31887/DCNS.2002.4.1/bbondy 22033824
    [Google Scholar]
  26. Dean J. Keshavan M. The neurobiology of depression: An integrated view. Asian J. Psychiatr. 2017 27 101 111 10.1016/j.ajp.2017.01.025 28558878
    [Google Scholar]
  27. Richelson E. Pharmacology of antidepressants. Mayo. Clin. Proc. 2001 76 5 511 527 10.4065/76.5.511 11357798
    [Google Scholar]
  28. Stewart R.M. Hood S.D. Rao P. Moore J.K. Runions K.C. Murphy S.E. Wong J.W.Y. Zepf F.D. Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: Study protocol for a randomised controlled trial. Trials 2018 19 1 434 10.1186/s13063‑018‑2791‑4 30097056
    [Google Scholar]
  29. Liu Y. Zhao J. Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Front. Psychol. 2018 9 2201 10.3389/fpsyg.2018.02201 30524332
    [Google Scholar]
  30. Leonard B.E. Stress, norepinephrine and depression. J. Psychiatry Neurosci. 2001 26 Suppl Suppl. S11 S16 11590964
    [Google Scholar]
  31. Silva H. Neurobiology of Depression. Etiopathogenic Theories and Models in Depression. Cham Springer 2022 34 1 155 166 10.1016/S0896‑6273(02)00653‑0
    [Google Scholar]
  32. Mikulska J. Juszczyk G. Gawrońska-Grzywacz M. Herbet M. HPA axis in the pathomechanism of depression and schizophrenia: New therapeutic strategies based on its participation. Brain Sci. 2021 11 10 1298 10.3390/brainsci11101298 34679364
    [Google Scholar]
  33. Ahmad M.H. Rizvi M.A. Fatima M. Mondal A.C. Pathophysiological implications of neuroinflammation mediated HPA axis dysregulation in the prognosis of cancer and depression. Mol. Cell. Endocrinol. 2021 520 111093 10.1016/j.mce.2020.111093 33253761
    [Google Scholar]
  34. Gold P.W. Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol. Psychiat. 2002 7 3 254 275 10.1038/sj.mp.4001032 11920153
    [Google Scholar]
  35. Young K. Singh G. Biological mechanisms of cancer-induced depression. Front. Psychiat. 2018 9 299 10.3389/fpsyt.2018.00299 30042700
    [Google Scholar]
  36. Pittenger C. Duman R.S. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2008 33 1 88 109 10.1038/sj.npp.1301574 17851537
    [Google Scholar]
  37. Duman R.S. Malberg J. Nakagawa S. D’Sa C. Neuronal plasticity and survival in mood disorders. Biol. Psychiat. 2000 48 8 732 739 10.1016/S0006‑3223(00)00935‑5 11063970
    [Google Scholar]
  38. Jacobs B.L. van Praag H. Gage F.H. Adult brain neurogenesis and psychiatry: A novel theory of depression. Mol. Psychiat. 2000 5 3 262 269 10.1038/sj.mp.4000712 10889528
    [Google Scholar]
  39. Henn F.A. Vollmayr B. Neurogenesis and depression: Etiology or epiphenomenon? Biol. Psychiat. 2004 56 3 146 150 10.1016/j.biopsych.2004.04.011 15271582
    [Google Scholar]
  40. Kim J. Lee S. Choi B.R. Yang H. Hwang Y. Park J.H.Y. LaFerla F.M. Han J.S. Lee K.W. Kim J. Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways. Mol. Nutr. Food Res. 2017 61 2 1600194 10.1002/mnfr.201600194 27735126
    [Google Scholar]
  41. Li X Zhao J Li Z Zhang L Huo Z. Applications of acupuncture therapy in modulating the plasticity of neurodegenerative disease and depression: Do MicroRNA and neurotrophin BDNF shed light on the underlying mechanism? Neural Plast. 2020 2020 8850653 10.1155/2020/8850653
    [Google Scholar]
  42. Henn F. Vollmayr B. Sartorius A. Mechanisms of depression: The role of neurogenesis. Drug Discov. Today Dis. Mech. 2004 1 4 407 411 10.1016/j.ddmec.2004.10.007
    [Google Scholar]
  43. Holtzheimer P.E. III Nemeroff C.B. Advances in the treatment of depression. NeuroRx 2006 3 1 42 56 10.1016/j.nurx.2005.12.007 16490412
    [Google Scholar]
  44. Bauer M. Severus E. Möller H.J. Young A.H. Pharmacological treatment of unipolar depressive disorders: Summary of WFSBP guidelines. Int. J. Psychiatry Clin. Pract. 2017 21 3 166 176 10.1080/13651501.2017.1306082 28367707
    [Google Scholar]
  45. Flory J.D. Yehuda R. Comorbidity between post-traumatic stress disorder and major depressive disorder: Alternative explanations and treatment considerations. Dialogues Clin. Neurosci. 2015 17 2 141 150 10.31887/DCNS.2015.17.2/jflory 26246789
    [Google Scholar]
  46. Maes M. Kubera M. Obuchowiczwa E. Goehler L. Brzeszcz J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett. 2011 32 1 7 24 21407167
    [Google Scholar]
  47. Cramer A.O.J. Waldorp L.J. van der Maas H.L.J. Borsboom D. Comorbidity: A network perspective. Behav. Brain Sci. 2010 33 2-3 137 150 10.1017/S0140525X09991567 20584369
    [Google Scholar]
  48. Bair M.J. Robinson R.L. Katon W. Kroenke K. Depression and pain comorbidity: A literature review. Arch. Intern. Med. 2003 163 20 2433 2445 10.1001/archinte.163.20.2433 14609780
    [Google Scholar]
  49. Makris A.P. Karianaki M. Tsamis K.I. Paschou S.A. The role of the gut-brain axis in depression: Endocrine, neural, and immune pathways. Hormones (Athens) 2021 20 1 1 12 10.1007/s42000‑020‑00236‑4 32827123
    [Google Scholar]
  50. Bojović K. Ignjatović Ð. Soković Bajić S. Vojnović Milutinović D. Tomić M. Golić N. Tolinački M. Gut microbiota dysbiosis associated with altered production of short chain fatty acids in children with neurodevelopmental disorders. Front. Cell. Infect. Microbiol. 2020 10 223 10.3389/fcimb.2020.00223 32509596
    [Google Scholar]
  51. Kupferberg A. Hasler G. The social cost of depression: Investigating the impact of impaired social emotion regulation, social cognition, and interpersonal behavior on social functioning. J. Affect. Disord. Rep. 2023 14 100631 10.1016/j.jadr.2023.100631
    [Google Scholar]
  52. Sanches M. Quevedo J. Soares J.C. New agents and perspectives in the pharmacological treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiat. 2021 106 110157 10.1016/j.pnpbp.2020.110157 33159975
    [Google Scholar]
  53. Read J. Williams J. Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects. Curr. Drug Saf. 2018 13 3 176 186 10.2174/1574886313666180605095130 29866014
    [Google Scholar]
  54. Ulrich S. Ricken R. Buspavanich P. Schlattmann P. Adli M. Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: A systematic review and comprehensive meta-analysis. J. Clin. Psychopharmacol. 2020 40 1 63 74 10.1097/JCP.0000000000001153 31834088
    [Google Scholar]
  55. Ferguson J.M. SSRI antidepressant medications: Adverse effects and tolerability. Prim. Care Companion J. Clin. Psychiat. 2001 3 1 22 27 15014625
    [Google Scholar]
  56. Anttila S.A.K. Leinonen E.V.J. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 7 3 249 264 10.1111/j.1527‑3458.2001.tb00198.x 11607047
    [Google Scholar]
  57. Nabavi S.M. Daglia M. Braidy N. Nabavi S.F. Natural products, micronutrients, and nutraceuticals for the treatment of depression: A short review. Nutr. Neurosci. 2017 20 3 180 194 10.1080/1028415X.2015.1103461 26613119
    [Google Scholar]
  58. Orlando J.M. Behavioral nutraceuticals and diets. Vet. Clin. North Am. Small Anim. Pract. 2018 48 3 473 495 10.1016/j.cvsm.2017.12.012 29429599
    [Google Scholar]
  59. Ramalingum N. Mahomoodally M.F. The therapeutic potential of medicinal foods. Adv. Pharmacol. Sci. 2014 2014 354264 10.1155/2014/354264 24822061
    [Google Scholar]
  60. World Health Organization. Nutraceuticals. 2023 Available from: https://www.who.int/foodsafety/fs_management/nut/en/ (Accessed on: March 23, 2023).
  61. Sachdeva V. Roy A. Bharadvaja N. Current prospects of nutraceuticals: A review. Curr. Pharm. Biotechnol. 2020 21 10 884 896 10.2174/1389201021666200130113441 32000642
    [Google Scholar]
  62. Prakash V. van Boekel M.A. Nutraceuticals: Possible future ingredients and food safety aspects. Ensuring global food safety. Amsterdam, Netherlands Elsevier 2010 333 338
    [Google Scholar]
  63. Makkar R. Behl T. Bungau S. Zengin G. Mehta V. Kumar A. Uddin M.S. Ashraf G.M. Abdel-Daim M.M. Arora S. Oancea R. Nutraceuticals in neurological disorders. Int. J. Mol. Sci. 2020 21 12 4424 10.3390/ijms21124424 32580329
    [Google Scholar]
  64. Sarris J. Ravindran A. Yatham L.N. Marx W. Rucklidge J.J. McIntyre R.S. Akhondzadeh S. Benedetti F. Caneo C. Cramer H. Cribb L. de Manincor M. Dean O. Deslandes A.C. Freeman M.P. Gangadhar B. Harvey B.H. Kasper S. Lake J. Lopresti A. Lu L. Metri N.J. Mischoulon D. Ng C.H. Nishi D. Rahimi R. Seedat S. Sinclair J. Su K.P. Zhang Z.J. Berk M. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The world federation of societies of biological psychiatry (WFSBP) and canadian network for mood and anxiety treatments (CANMAT) taskforce. World J. Biol. Psychiat. 2022 23 6 424 455 10.1080/15622975.2021.2013041 35311615
    [Google Scholar]
  65. Shekelle P.G. Hardy M.L. Morton S.C. Maglione M. Mojica W.A. Suttorp M.J. Rhodes S.L. Jungvig L. Gagné J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. JAMA 2003 289 12 1537 1545 10.1001/jama.289.12.1537 12672771
    [Google Scholar]
  66. Dureja H. Kaushik D. Kumar V. Developments in nutraceuticals. Indian J. Pharmacol. 2003 35 6 363 372
    [Google Scholar]
  67. Ghani U. Naeem M. Rafeeq H. Imtiaz U. Amjad A. Ullah S. Rehman A. Qasim F. A novel approach towards nutraceuticals and biomedical applications. Schol. Int. J. Biochem. 2019 2 10 245 252 10.36348/SIJB.2019.v02i10.001
    [Google Scholar]
  68. Maurya A.P. Chauhan J. Yadav D.K. Gangwar R. Maurya V.K. Nutraceuticals and their impact on human health. Preparation of Phytopharmaceuticals for the Management of Disorders. Amsterdam, Netherlands Elsevier 2021 229 254 10.1016/B978‑0‑12‑820284‑5.00011‑3
    [Google Scholar]
  69. Thebaudin J.Y. Lefebvre A.C. Harrington M. Bourgeois C.M. Dietary fibres: Nutritional and technological interest. Trends Food Sci. Technol. 1997 8 2 41 48 10.1016/S0924‑2244(97)01007‑8
    [Google Scholar]
  70. Xia Y. Liu Y. Zhang S. Zhang Q. Liu L. Meng G. Wu H. Sun S. Wang X. Zhou M. Jia Q. Song K. Wu Q. Niu K. Zhao Y. Associations between different types and sources of dietary fibre intake and depressive symptoms in a general population of adults: A cross-sectional study. Br. J. Nutr. 2021 125 11 1281 1290 10.1017/S0007114520003566 32921321
    [Google Scholar]
  71. Rosa A. Nieddu M. Masala C. Marincola F.C. Porcedda S. Piras A. Waste salt from the manufacturing process of mullet bottarga as source of oil with nutritional and nutraceutical properties. J. Sci. Food Agric. 2020 100 15 5363 5372 10.1002/jsfa.10584 32542835
    [Google Scholar]
  72. Dahiya D. Nigam P.S. Probiotics, prebiotics, synbiotics, and fermented foods as potential biotics in nutrition improving health via microbiome-gut-brain axis. Fermentation (Basel) 2022 8 7 303 10.3390/fermentation8070303
    [Google Scholar]
  73. Dahiya D. Nigam P.S. The gut microbiota influenced by the intake of probiotics and functional foods with prebiotics can sustain wellness and alleviate certain ailments like gut-inflammation and colon-cancer. Microorganisms 2022 10 3 665 10.3390/microorganisms10030665 35336240
    [Google Scholar]
  74. Sánchez B. Delgado S. Blanco-Míguez A. Lourenço A. Gueimonde M. Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 2017 61 1 1600240 10.1002/mnfr.201600240 27500859
    [Google Scholar]
  75. Chanda S. Tiwari R.K. Kumar A. Singh K. Nutraceuticals inspiring the current therapy for lifestyle diseases. Adv. Pharmacol. Sci. 2019 2019 6908716 10.1155/2019/6908716 30755770
    [Google Scholar]
  76. Singh J. Sinha S. Classification, regulatory acts and applications of nutraceuticals for health. Int. J. Pharma. Bio. Sci. 2012 2 1 177 187
    [Google Scholar]
  77. Hussain S.A. Panjagari N.R. Singh R.R.B. Patil G.R. Potential herbs and herbal nutraceuticals: Food applications and their interactions with food components. Crit. Rev. Food Sci. Nutr. 2015 55 1 94 122 10.1080/10408398.2011.649148 24915396
    [Google Scholar]
  78. Nalini D. Selvaraj J. Kumar G.S. Herbal nutraceuticals: Safe and potent therapeutics to battle tumor hypoxia. J. Cancer Res. Clin. Oncol. 2020 146 1 1 18 10.1007/s00432‑019‑03068‑x 31724069
    [Google Scholar]
  79. Williams R.J. Mohanakumar K. Beart P.M. Neuro-nutraceuticals: Further insights into their promise for brain health. Amsterdam, Netherlands Elsevier 2016 1 3
    [Google Scholar]
  80. Nasri H. Baradaran A. Shirzad H. Rafieian-Kopaei M. New concepts in nutraceuticals as alternative for pharmaceuticals. Int. J. Prev. Med. 2014 5 12 1487 1499 25709784
    [Google Scholar]
  81. Shahrajabian M.H. Sun W. Cheng Q. Clinical aspects and health benefits of ginger (Zingiber officinale) in both traditional Chinese medicine and modern industry. Acta. Agric. Scand. B. Soil Plan. Sci. 2019 69 6 546 556 10.1080/09064710.2019.1606930
    [Google Scholar]
  82. Ansary J. Forbes-Hernández T.Y. Gil E. Cianciosi D. Zhang J. Elexpuru-Zabaleta M. Simal-Gandara J. Giampieri F. Battino M. Potential health benefit of garlic based on human intervention studies: A brief overview. Antioxidants 2020 9 7 619 10.3390/antiox9070619 32679751
    [Google Scholar]
  83. Biswas T. Mathur A. Gupta V. Luqman S. Mathur A.K. Elicitation and phenylalanine precursor feeding based modulation of in vitro anthocyanin production, enzyme activity and gene expression in an Indian ginseng congener- Panax sikkimensis Ban. Ind. Crops Prod. 2020 145 111986 10.1016/j.indcrop.2019.111986
    [Google Scholar]
  84. Novelli M. Masiello P. Beffy P. Menegazzi M. Protective role of St. John’s wort and its components hyperforin and hypericin against diabetes through inhibition of inflammatory signaling: Evidence from in vitro and in vivo studies. Int. J. Mol. Sci. 2020 21 21 8108 10.3390/ijms21218108 33143088
    [Google Scholar]
  85. Singh H. Khar A. Potential of onion (Allium cepa) as traditional therapeutic and functional food: An update. Ind. J. Agricult. Sci. 2022 92 11 1291 1297 10.56093/ijas.v92i11.123235
    [Google Scholar]
  86. Rahman M.M. Amin R. Afroz T. Das J. Pharmaceutical, therapeutically and nutraceutical potential of aloe vera: A mini-review. J. Pharm. Res. Int. 2021 33 37A 109 118 10.9734/jpri/2021/v33i37A31986
    [Google Scholar]
  87. Thiruvengadam M. Shariati M.A. Akram M. Zainab R. Daniyal M. Bankole M.M. Rebezov M. Okuskhanova E. Herbal medicine for the management of laxative activity. Curr. Pharm. Biotechnol. 2022 23 10 1269 1283 10.2174/1389201022666210812121328 34387161
    [Google Scholar]
  88. Sharma N. Radha Kumar M. Zhang B. Kumari N. Singh D. Chandran D. Sarkar T. Dhumal S. Sheri V. Dey A. Rajalingam S. Viswanathan S. Mohankumar P. Vishvanathan M. Sathyaseelan S.K. Lorenzo J.M. Aegle marmelos (L.) Correa: An underutilized fruit with high nutraceutical values: A review. Int. J. Mol. Sci. 2022 23 18 10889 10.3390/ijms231810889 36142805
    [Google Scholar]
  89. Shareena G. Kumar D. Traversing through half a century research timeline on Ginkgo biloba, in transforming a botanical rarity into an active functional food ingredient. Biomed. Pharmacother. 2022 153 113299 10.1016/j.biopha.2022.113299 35750010
    [Google Scholar]
  90. Vishvakarma P. Mandal S. Verma A. A review on current aspects of nutraceuticals and dietary supplements. Int. J. Pharma. Profess. Res. 2023 14 1 78 91 10.48165/ijppronline.2023.14107
    [Google Scholar]
  91. Bakr A.F. Shao P. Farag M.A. Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review. Phytomedicine 2022 99 153999 10.1016/j.phymed.2022.153999 35220130
    [Google Scholar]
  92. Hay E. Lucariello A. Contieri M. Esposito T. De Luca A. Guerra G. Perna A. Therapeutic effects of turmeric in several diseases: An overview. Chem. Biol. Interact. 2019 310 108729 10.1016/j.cbi.2019.108729 31255636
    [Google Scholar]
  93. Evans M. Arentz S. The influence of Hydrastis canadensis on the gastrointestinal microbiota – beneficial or detrimental effects? A critical review to update naturopathic and western herbal clinical practice. Austral. J. Herb. Naturop. Med. 2022 34 4 156 163 10.33235/ajhnm.34.4.156‑163
    [Google Scholar]
  94. Abdolmaleki A. Akram M. Saeed M.M. Asadi A. Kajkolah M. Herbal medicine as neuroprotective potential agent in human and animal models: A historical overview. J. Pharma. Care 2020 8 2 75 82 10.18502/jpc.v8i2.3832
    [Google Scholar]
  95. Biswas D. Mandal S. Chatterjee Saha S. Tudu C.K. Nandy S. Batiha G.E.S. Shekhawat M.S. Pandey D.K. Dey A. Ethnobotany, phytochemistry, pharmacology, and toxicity of Centella asiatica (L.) Urban: A comprehensive review. Phytother. Res. 2021 35 12 6624 6654 10.1002/ptr.7248 34463404
    [Google Scholar]
  96. Gupta S. Chauhan D. Mehla K. Sood P. Nair A. An overview of nutraceuticals: Current scenario. J. Basic Clin. Pharm. 2010 1 2 55 62 24825966
    [Google Scholar]
  97. Borkar N. Saurabh S. Rathore K. Pandit A. Khandelwal K. An insight on nutraceuticals. PharmaTutor. 2015 3 8 13 23
    [Google Scholar]
  98. AlAli M. Alqubaisy M. Aljaafari M.N. AlAli A.O. Baqais L. Molouki A. Abushelaibi A. Lai K.S. Lim S.H.E. Nutraceuticals: Transformation of conventional foods into health promoters/disease preventers and safety considerations. Molecules 2021 26 9 2540 10.3390/molecules26092540 33925346
    [Google Scholar]
  99. Drake P.M.W. Szeto T.H. Paul M.J. Teh A.Y.H. Ma J.K.C. Recombinant biologic products versus nutraceuticals from plants – a regulatory choice? Br. J. Clin. Pharmacol. 2017 83 1 82 87 10.1111/bcp.13041 27297459
    [Google Scholar]
  100. Gutiérrez-del-Río I. Fernández J. Lombó F. Plant nutraceuticals as antimicrobial agents in food preservation: Terpenoids, polyphenols and thiols. Int. J. Antimicrob. Agents 2018 52 3 309 315 10.1016/j.ijantimicag.2018.04.024 29777759
    [Google Scholar]
  101. Kaur G. Mukundan S. Wani V. Kumar M.S. Nutraceuticals in the management and prevention of metabolic syndrome. Austin J. Pharmacol. Ther. 2015 3 1 1063
    [Google Scholar]
  102. Zhang Y.J. Gan R.Y. Li S. Zhou Y. Li A.N. Xu D.P. Li H.B. Review Antioxidant phytochemical for the prevention and treatment of chronic disease. Molecules 2015 20 12 21138 21156 10.3390/molecules201219753 26633317
    [Google Scholar]
  103. Ansari S.H. Chauhan B. Kumar G. Kalam N. Current concepts and prospects of herbal nutraceutical: A review. J. Adv. Pharm. Technol. Res. 2013 4 1 4 8 10.4103/2231‑4040.107494 23662276
    [Google Scholar]
  104. Das L. Bhaumik E. Raychaudhuri U. Chakraborty R. Role of nutraceuticals in human health. J. Food Sci. Technol. 2012 49 2 173 183 10.1007/s13197‑011‑0269‑4 23572839
    [Google Scholar]
  105. Benvenga S. Feldt-Rasmussen U. Bonofiglio D. Asamoah E. Nutraceutical supplements in the thyroid setting: Health benefits beyond basic nutrition. Nutrients 2019 11 9 2214 10.3390/nu11092214 31540254
    [Google Scholar]
  106. Adu-Afarwuah S. Lartey A. Dewey K.G. Meeting nutritional needs in the first 1000 days: A place for small‐quantity lipid‐based nutrient supplements. Ann. N. Y. Acad. Sci. 2017 1392 1 18 29 10.1111/nyas.13328 28319655
    [Google Scholar]
  107. Blanco-Llamero C. Fonseca J. Durazzo A. Lucarini M. Santini A. Señoráns F.J. Souto E.B. Nutraceuticals and food-grade lipid nanoparticles: From natural sources to a circular bioeconomy approach. Foods 2022 11 15 2318 10.3390/foods11152318 35954085
    [Google Scholar]
  108. Chopra A.S. Lordan R. Horbańczuk O.K. Atanasov A.G. Chopra I. Horbańczuk J.O. Jóźwik A. Huang L. Pirgozliev V. Banach M. Battino M. Arkells N. The current use and evolving landscape of nutraceuticals. Pharmacol. Res. 2022 175 106001 10.1016/j.phrs.2021.106001 34826602
    [Google Scholar]
  109. Brower V. A nutraceutical a day may keep the doctor away. EMBO Rep. 2005 6 8 708 711 10.1038/sj.embor.7400498 16065061
    [Google Scholar]
  110. Pillitteri J. Shiffman S. Rohay J. Harkins A. Burton S. Wadden T. Use of dietary supplements for weight loss in the United States: Results of a national survey. Obesity. 2008 16 4 790 796 10.1038/oby.2007.136 18239570
    [Google Scholar]
  111. Gupta R.C. Srivastava A. Lall R. Toxicity potential of nutraceuticals. Meth. Mol. Biol. 2018 1800 367 394 10.1007/978‑1‑4939‑7899‑1_18 29934903
    [Google Scholar]
  112. Sarris J. Murphy J. Mischoulon D. Papakostas G.I. Fava M. Berk M. Ng C.H. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am. J. Psychiat. 2016 173 6 575 587 10.1176/appi.ajp.2016.15091228 27113121
    [Google Scholar]
  113. Sarris J. Logan A.C. Akbaraly T.N. Amminger G.P. Balanzá-Martínez V. Freeman M.P. Hibbeln J. Matsuoka Y. Mischoulon D. Mizoue T. Nanri A. Nishi D. Ramsey D. Rucklidge J.J. Sanchez-Villegas A. Scholey A. Su K.P. Jacka F.N. Nutritional medicine as mainstream in psychiatry. Lancet Psychiat. 2015 2 3 271 274 10.1016/S2215‑0366(14)00051‑0 26359904
    [Google Scholar]
  114. Sarris J. Byrne G.J. Bousman C. Stough C. Murphy J. MacDonald P. Adams L. Nazareth S. Oliver G. Cribb L. Savage K. Menon R. Chamoli S. Berk M. Ng C. Mischoulon D. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. Eur. Neuropsychopharmacol. 2018 28 10 1126 1136 10.1016/j.euroneuro.2018.07.098 30115553
    [Google Scholar]
  115. Grosso G. Pajak A. Marventano S. Castellano S. Galvano F. Bucolo C. Drago F. Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: A comprehensive meta-analysis of randomized clinical trials. PLoS One 2014 9 5 e96905 10.1371/journal.pone.0096905 24805797
    [Google Scholar]
  116. Grosso G. Galvano F. Marventano S. Malaguarnera M. Bucolo C. Drago F. Caraci F. Omega-3 fatty acids and depression: Scientific evidence and biological mechanisms. Oxid. Med. Cell. Longev. 2014 2014 1 16 10.1155/2014/313570 24757497
    [Google Scholar]
  117. Alli S.R. Gorbovskaya I. Liu J.C.W. Kolla N.J. Brown L. Müller D.J. The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: A systematic review of clinical trials and observational studies. Int. J. Mol. Sci. 2022 23 9 4494 10.3390/ijms23094494 35562885
    [Google Scholar]
  118. Barber T.M. Kabisch S. Pfeiffer A.F.H. Weickert M.O. The health benefits of dietary fibre. Nutrients 2020 12 10 3209 10.3390/nu12103209 33096647
    [Google Scholar]
  119. Sarris J. Byrne G.J. Stough C. Bousman C. Mischoulon D. Murphy J. Macdonald P. Adams L. Nazareth S. Oliver G. Cribb L. Savage K. Menon R. Chamoli S. Berk M. Ng C.H. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. J. Affect. Disord. 2019 245 1007 1015 10.1016/j.jad.2018.11.092 30699842
    [Google Scholar]
  120. Chiu H.F. Venkatakrishnan K. Wang C.K. The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: A mini-review. J. Tradit. Complement. Med. 2020 10 5 434 439 10.1016/j.jtcme.2020.03.008 32953558
    [Google Scholar]
  121. Dao V.H. Hoang L.B. Trinh T.O. Tran T.T.T. Dao V.L. Psychobiotics for patients with chronic gastrointestinal disorders having anxiety or depression symptoms. J. Multidiscip. Healthc. 2021 14 1395 1402 10.2147/JMDH.S312316 34140777
    [Google Scholar]
  122. Cunningham M. Azcarate-Peril M.A. Barnard A. Benoit V. Grimaldi R. Guyonnet D. Holscher H.D. Hunter K. Manurung S. Obis D. Petrova M.I. Steinert R.E. Swanson K.S. van Sinderen D. Vulevic J. Gibson G.R. Shaping the future of probiotics and prebiotics. Trends Microbiol. 2021 29 8 667 685 10.1016/j.tim.2021.01.003 33551269
    [Google Scholar]
  123. Mocayar Marón F.J. Ferder L. Reiter R.J. Manucha W. Daily and seasonal mitochondrial protection: Unraveling common possible mechanisms involving vitamin D and melatonin. J. Steroid Biochem. Mol. Biol. 2020 199 105595 10.1016/j.jsbmb.2020.105595 31954766
    [Google Scholar]
  124. Jain R. Manning S. Cutler A.J. Good, better, best: Clinical scenarios for the use of L-methylfolate in patients with MDD. CNS Spectr. 2020 25 6 750 764 10.1017/S1092852919001469 31833826
    [Google Scholar]
  125. Mehrpooya M. Yasrebifar F. Haghighi M. Mohammadi Y. Jahangard L. Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: A double-blind controlled clinical trial. J. Clin. Psychopharmacol. 2018 38 5 460 466 10.1097/JCP.0000000000000938 30106880
    [Google Scholar]
  126. Abdelmeguid N.E. Hammad T.M. Abdel-Moneim A.M. Salam S.A. Effect of Epigallocatechin-3-gallate on Stress-Induced Depression in a Mouse Model: Role of Interleukin-1β and Brain-Derived Neurotrophic Factor. Neurochem. Res. 2022 47 11 3464 3475 10.1007/s11064‑022‑03707‑9 35939172
    [Google Scholar]
  127. Rondanelli M. Opizzi A. Solerte S.B. Trotti R. Klersy C. Cazzola R. Administration of a dietary supplement ( N -oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: A randomized controlled trial. Br. J. Nutr. 2009 101 3 457 464 10.1017/S0007114508024008 18590587
    [Google Scholar]
  128. Ceskova E. Silhan P. Novel treatment options in depression and psychosis. Neuropsychiatr. Dis. Treat. 2018 14 741 747 10.2147/NDT.S157475 29559781
    [Google Scholar]
  129. van der Burg K.P. Cribb L. Firth J. Karmacoska D. Mischoulon D. Byrne G.J. Bousman C. Stough C. Murphy J. Oliver G. Berk M. Ng C.H. Sarris J. EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. Eur. J. Nutr. 2020 59 6 2439 2447 10.1007/s00394‑019‑02090‑6 31555976
    [Google Scholar]
  130. Sarris J. Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders. Australas. Psychiat. 2017 25 4 369 372 10.1177/1039856216689533 28135835
    [Google Scholar]
  131. Lee G. Bae H. Therapeutic effects of phytochemicals and medicinal herbs on depression. Biomed. Res. Int. 2017 2017 6596241 10.1155/2017/6596241 28503571
    [Google Scholar]
  132. Linde K. Berner M.M. Kriston L. St John's wort for major depression. Cochr. Datab. Syst. Rev. 2008 8 4 CD000448 10.1002/14651858.CD000448.pub3 18843608
    [Google Scholar]
  133. Gaster B. Holroyd J. St John’s wort for depression: A systematic review. Arch. Intern. Med. 2000 160 2 152 156 10.1001/archinte.160.2.152 10647752
    [Google Scholar]
  134. Emanuel A.M. Moore T.R. Ghazvini P. Considerations for the use of alternative therapies in the treatment of depression. J. Pharm. Pract. 2001 14 6 551 559 10.1177/089719001129040892
    [Google Scholar]
  135. Zahiruddin S. Basist P. Parveen A. Parveen R. Khan W. Gaurav Ahmad S. Ashwagandha in brain disorders: A review of recent developments. J. Ethnopharmacol. 2020 257 112876 10.1016/j.jep.2020.112876 32305638
    [Google Scholar]
  136. Paul S. Chakraborty S. Anand U. Dey S. Nandy S. Ghorai M. Saha S.C. Patil M.T. Kandimalla R. Proćków J. Dey A. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed. Pharmacother. 2021 143 112175 10.1016/j.biopha.2021.112175 34649336
    [Google Scholar]
  137. Kenda M. Kočevar Glavač N. Nagy M. Sollner Dolenc M. Medicinal plants used for anxiety, depression, or stress treatment: An update. Molecules 2022 27 18 6021 10.3390/molecules27186021 36144755
    [Google Scholar]
  138. Ogata K. Ataka K. Suzuki H. Yagi T. Okawa A. Fukumoto T. Zhang B. Nakata M. Yada T. Lavender oil reduces depressive mood in healthy individuals and enhances the activity of single oxytocin neurons of the hypothalamus isolated from mice: A preliminary study. Evid. Base. Compl. Alternat. Med. 2020 2020 5418586 10.1155/2020/5418586 32733584
    [Google Scholar]
  139. Rivers Z. Xing C. Narayanapillai S. Kava as a pharmacotherapy of anxiety disorders: Promises and concerns. J. Med. Chem. 2016 6 81 87
    [Google Scholar]
  140. Jafarpoor N. Abbasi-Maleki S. Asadi-Samani M. Khayatnouri M.H. Evaluation of antidepressant-like effect of hydroalcoholic extract of Passiflora incarnata in animal models of depression in male mice. J. Herb. Med. Pharmacol. 2014 3 1 41 45
    [Google Scholar]
  141. Akbar S. Depression, Antidepressant Drugs and St. John's Wort: Myths, Lies and Manipulations. Bloomington, Indiana Trafford Publishing 2013 222
    [Google Scholar]
  142. Levin V Booth R Minassian S. Bleeding Disorders and ART. Textbook of Assisted Reproduction Boca Raton, FL CRC Press 2020 307 323 10.1007/978‑981‑15‑2377‑9_35
    [Google Scholar]
  143. Travica N. Teasdale S. Marx W. Nutraceuticals in mood disorders: Current knowledge and future directions. Curr. Opin. Psychiat. 2023 36 1 54 59 10.1097/YCO.0000000000000826 36044293
    [Google Scholar]
  144. Mocking R.J.T. Harmsen I. Assies J. Koeter M.W.J. Ruhé H.G. Schene A.H. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl. Psychiat. 2016 6 3 e756 10.1038/tp.2016.29 26978738
    [Google Scholar]
  145. Lopresti A.L. Maes M. Maker G.L. Hood S.D. Drummond P.D. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J. Affect. Disord. 2014 167 368 375 10.1016/j.jad.2014.06.001 25046624
    [Google Scholar]
  146. Shahpiri Z. Bahramsoltani R. Hosein Farzaei M. Farzaei F. Rahimi R. Phytochemicals as future drugs for Parkinson’s disease: A comprehensive review. Rev. Neurosci. 2016 27 6 651 668 10.1515/revneuro‑2016‑0004 27124673
    [Google Scholar]
  147. Messaoudi M. Lalonde R. Violle N. Javelot H. Desor D. Nejdi A. Bisson J.F. Rougeot C. Pichelin M. Cazaubiel M. Cazaubiel J.M. Assessment of psychotropic-like properties of a probiotic formulation ( Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2011 105 5 755 764 10.1017/S0007114510004319 20974015
    [Google Scholar]
  148. Lopresti A.L. Drummond P.D. Saffron (Crocus sativus) for depression: A systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum. Psychopharmacol. 2014 29 6 517 527 10.1002/hup.2434 25384672
    [Google Scholar]
  149. Lin K. Li Y. Toit E.D. Wendt L. Sun J. Effects of polyphenol supplementations on improving depression, anxiety, and quality of life in patients with depression. Front. Psychiat. 2021 12 765485 10.3389/fpsyt.2021.765485 34819888
    [Google Scholar]
  150. Spedding S. Vitamin D and depression: A systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients 2014 6 4 1501 1518 10.3390/nu6041501 24732019
    [Google Scholar]
  151. Sanoobar M. Dehghan P. Khalili M. Azimi A. Seifar F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial. Nutr. Neurosci. 2016 19 3 138 143 10.1179/1476830515Y.0000000002 25603363
    [Google Scholar]
  152. Boyle N. Lawton C. Dye L. The effects of magnesium supplementation on subjective anxiety and stress—a systematic review. Nutrients 2017 9 5 429 10.3390/nu9050429 28445426
    [Google Scholar]
  153. Tarleton E.K. Littenberg B. Magnesium intake and depression in adults. J. Am. Board Fam. Med. 2015 28 2 249 256 10.3122/jabfm.2015.02.140176 25748766
    [Google Scholar]
  154. Hidese S. Ogawa S. Ota M. Ishida I. Yasukawa Z. Ozeki M. Kunugi H. Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: A randomized controlled trial. Nutrients 2019 11 10 2362 10.3390/nu11102362 31623400
    [Google Scholar]
  155. Swardfager W. Herrmann N. Mazereeuw G. Goldberger K. Harimoto T. Lanctôt K.L. Zinc in depression: A meta-analysis. Biol. Psychiat. 2013 74 12 872 878 10.1016/j.biopsych.2013.05.008 23806573
    [Google Scholar]
  156. Shaw K.A. Turner J. Del Mar C. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Libr. 2002 2010 1 10.1002/14651858.CD003198
    [Google Scholar]
  157. Coppen A. Bolander-Gouaille C. Treatment of depression: Time to consider folic acid and vitamin B12. J. Psychopharmacol. 2005 19 1 59 65 10.1177/0269881105048899 15671130
    [Google Scholar]
  158. Puri V. Nagpal M. Singh I. Singh M. Dhingra G.A. Huanbutta K. Dheer D. Sharma A. Sangnim T. A comprehensive review on nutraceuticals: Therapy support and formulation challenges. Nutrients 2022 14 21 4637 10.3390/nu14214637 36364899
    [Google Scholar]
  159. Myhren F. Hsls P.A. Oem N. Storsve A.N. Krill oil composition enriched in LPC-DHA and LPC-EPA. Patent WO 2021/202680 A3 2021
  160. Hallaraker H. Lipid compositions with DHA content. Patent US11135230B2 2021
  161. Dror B.G. Platt D. Farkash O. Zuabi R. Glucerophospolipids for the improvement of cognitive functions. Patent CA2847644C 2016
  162. Patel A. Timothy W. Compositions and methods for improving sleep using a nutraceutical formulation. Patent US 2015/0071993 A1 2015
  163. Patel A. Timothy W. Annette M. Nutraceutical formulation for treatment of anxiety and depression. Patent US 2015/0320814 A1 2015
  164. Ipierro G. Steven A.G. Bisynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycaemia, alzheimer’s disease, sleep disorders, parkinson’s disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like. Patent US 8,252,321 B2 2012
  165. Angel J. Rangel O. Phyto-nutraceutical synergistic composition for parkinson’s disease. Patent US 2008/0118583 A1 2008
  166. Pettegrew J.W. Samuel G. Kanagasabai P. Compounds, Compositions and methods for treating neuropsychatrc dsorders. Patent US 2006/0088614 A1 2006
  167. Dror G.B. Plat D. Orly F. Rassan Z. Zohar B. Avidor S. Dori P. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions. Patent US 2006/0241080 A1 2006
  168. Lecerf J.-M. Depressed mood and anhedonia in healthy adults (MOOD5). Patent NCT05306093 2022
  169. Lallemand H. The effects of a novel probiotic supplement on menopausal symptoms and bone health (MPS). Patent NCT04001088 2022
/content/journals/rafna/10.2174/012772574X361750250323111150
Loading
Nutraceuticals in Depression Management: Current Evidence and Perspectives
Bentham Science Publishers ; https://doi.org/10.2174/012772574X361750250323111150
/content/journals/rafna/10.2174/012772574X361750250323111150
/content/journals/rafna/10.2174/012772574X361750250323111150
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: dietary fibers ; nutraceutical ; treatment ; Depression ; Omega-3 polyunsaturated fatty acids ; phytochemicals

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test